65,437 trials
Anxiety Disorder
Primary: Number of Responders Based on Clinician Global Impression-Anxiety Improvement — 20; 9 Participants — p=<.05
Advanced/Metastatic Breast Cancer
Primary: Number of Participants With Objective Response Based on Data Review Committee's Assessment — 19; 0; 19 participants
HIV Infections
Primary: Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response…
Metastatic Androgen Independent Prostate Cancer
Primary: Safety of APC8015F by Review of Reported Adverse Events — 109 Participants
Epilepsy · Bipolar Disorder
Primary: Birth Outcomes by Earliest Pregnancy Trimester of Exposure to Lamotrigine Monotherapy — 31; 4; 1; 0 infants
Pharmacokinetics · Drug Interactions · Pharmacodynamics
Primary: AUC0-24h of Free Ezetimibe (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe) on Study Day 15 — 51.9 ng*h/ml
Coronary Heart Disease · Hypercholesterolemia
Primary: Percentage of Patients Receiving Each Variant of Modified Lipid-lowering Therapy: Statin Dose Titration, Administration of a New Statin, Administration of a Ezetimibe in…
Cervical Intraepithelial Neoplasia · Uterine Cervical Dysplasia
Primary: Pathological Response — 20; 24 participants
Carcinoma
Primary: Maximum Tolerated Dose (MTD) of Sorafenib in Combination With Paclitaxel and Carboplatin — 400 mg
Diabetes
Primary: Number of Participants Who Rated Successful (<=3) by Healthcare Professionals When Participants Performed Specific Software Tasks — 50; 50; 50; 50 participants
Anxiety Disorders
Primary: Change in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score — -10.1; -10.4; -10.8; -9.5 Units on scale
Breast Neoplasms
Primary: Progression-Free Survival (PFS) — 7.4; 9.2 Months — p=0.9986
Secondary Hypogonadism
Primary: Sperm Concentration — 0.54; 72.8; 3.00; 182.6 millions sperm/mL — p=0.118
Healthy
Primary: Cmax of Drospirenone(Maximum Observed Concentration of Drug Substance in Plasma) — 52.77; 53.65 ng/mL
Cardiac Arrest
Primary: Median Compression Depth (mm) — 30; 41; 42; 48 millimeters — p=.05